Document is current
Any future updates will be listed below
-
Authors
Hunt, Kelly K.
Suman, Vera J.
Wingate, Hannah F.
Leitch, A. Marilyn
Unzeitig, Gary
Boughey, Judy C.
Meric-Bernstam, Funda
Ellis, Matthew J.
Olson, John
-
Funding
Funding for this research was provided by:
National Cancer Institute (U10CA180821, U10CA180858, U10CA180870, U10CA180882, U24CA196171, UG1CA232760)
- License Information
-
More Information
Article History
Received: 2 September 2022
Accepted: 26 October 2022
First Online: 18 January 2023
Disclosures
: Kelly K. Hunt: Consulting or Advisory Role: Armada Health, AstraZeneca, Merck & Co.; Research funding to MD Anderson Cancer Center: Cairn Surgical, Eli Lilly & Co, Lumicell. Vera J. Suman: No relationship to disclose. Hannah F. Wingate: No relationship to disclose. A. Marilyn Leitch: Consulting or Advisory Role: Celgene, Genomic Health, Castle Biosciences. Gary Unzeitig: No relationships to disclose. Funda Meric-Bernstam: Membership on Board of Directors or Advisory Committees (includes consulting). Protai Bio Ltd; Astra Zeneca; Seagen (formerly Seattle Genetics); Zymeworks; OnCusp Therapeutics; Harbinger Health; Tallac Therapeutics; Daiichi Sankyo; Lengo Therapeutics; Sanofi Pharmaceuticals; FogPharma; Karyopharm; LOXO Oncology; Biovica; F. Hoffmann La-Roche. Judy C. Boughey: Consulting or Advisory Role: Cairn Surgical, SymBioSis; Research funding to Mayo Clinic: Eli Lilly & Co. John Olson: Stock or Other Ownership: Core Prognostex. Matthew J. Ellis: Employment: AstraZeneca; Patents, Royalties, Other Intellectual Property: PAM50-based diagnostics, including Prosigna (Veracyte).
